Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:JNCE

Jounce Therapeutics (JNCE) Stock Price, News & Analysis

Jounce Therapeutics logo

About Jounce Therapeutics Stock (NASDAQ:JNCE)

Key Stats

Today's Range
$1.88
$1.93
50-Day Range
$1.84
$1.94
52-Week Range
$0.58
$5.87
Volume
11.60 million shs
Average Volume
2.46 million shs
Market Capitalization
$98.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

JNCE Stock Analysis - Frequently Asked Questions

Jounce Therapeutics, Inc. (NASDAQ:JNCE) announced its earnings results on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15.

Jounce Therapeutics (JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Jounce Therapeutics investors own include CRISPR Therapeutics (CRSP), Exelixis (EXEL), Meta Platforms (META), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ), Novavax (NVAX) and OPKO Health (OPK).

Company Calendar

Last Earnings
11/04/2021
Today
11/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:JNCE
Fax
N/A
Employees
137
Year Founded
N/A

Profitability

Net Income
$-50,920,000.00
Pretax Margin
-61.93%

Debt

Sales & Book Value

Annual Sales
$82 million
Book Value
$3.54 per share

Miscellaneous

Free Float
48,993,000
Market Cap
$98.94 million
Optionable
Optionable
Beta
0.75
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:JNCE) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners